Search

everythinglearnresearchcommunity

for

Search:↓

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

Energy healing treatment improved flutamide's solubility and stability, potentially enhancing its effectiveness for prostate cancer.

Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Corticosteroids, especially prednisone, improve short-term muscle strength in Duchenne muscular dystrophy but have manageable side effects.

5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.

New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.

Wnt genes help starfish regrow arms by aiding wound healing and cell development.

Early detection and infection prevention are crucial for improving survival in pediatric lupus patients with aplastic anemia.

Women with idiopathic hirsutism and PCOS have higher RBP4 levels, and PCOS is linked to greater insulin resistance; weight management may help both conditions.

Herbal supplements like Berberine, Cinnamon, and Fenugreek may be affordable alternatives for managing PCOS.

Oxidative stress, not insulin resistance, is linked to diffuse hair loss.

Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.

Different immune responses cause hair loss in scalp diseases, with unique patterns in scalp psoriasis possibly protecting against hair loss.

A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

The SBN system effectively assesses alopecia areata severity and predicts its course.

The document encourages attending the 2023 Dermatology Nurses' Association Convention.

Short anagen syndrome causes short hair that may grow longer after puberty.

The updated SALT II tool offers a more precise way to measure scalp hair loss.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.

In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.

Vitamin D deficiency is common in people with certain types of hair loss, like alopecia areata and female pattern hair loss.

SSAT is a key enzyme affecting cell growth and metabolism, with potential but risky use in disease treatment.

Necrosulfonamide helps hair grow by blocking a protein linked to hair loss.

A new tool simplifies alopecia areata severity scoring but needs validation.

Acitretin significantly reduced inflammatory attacks in a woman with Naevus Comedonicus Syndrome but caused side effects.

People with hair loss are more likely to have anxiety.